Claims
- 1. A method of inhibiting the interaction of a cell bearing mammalian CC-chemokine receptor 2 with a ligand thereof, comprising contacting said cell with an effective amount of an antibody or antigen-binding fragment thereof which binds to the amino-terminal domain of mammalian CC-chemokine receptor 2 and inhibits binding of said ligand to the receptor.
- 2. A method according to claim 1, wherein said cell is selected from the group consisting of lymphocytes, monocytes, granulocytes, T cells, basophils, and cells comprising a recombinant nucleic acid encoding CCR2 or a portion thereof.
- 3. A method according to claim 2, wherein said T cells are selected from the group consisting of CD8+ cells, CD25+ cells, CD4+ cells and CD45RO+ cells.
- 4. A method according to claim 1, wherein said mammalian CC-chemokine receptor 2 is a human CC-chemokine receptor 2
- 5. A method according to claim 1, wherein said ligand is a chemokine.
- 6. A method according to claim 5 wherein said chemokine is selected from the group consisting of MCP-1, MCP-2, MCP-3, MCP-4 and combinations thereof.
- 7. A method according to claim 1, wherein said antibody or antigen-binding fragment is a monoclonal antibody or antigen-binding fragment thereof.
- 8. A method according to claim 1, wherein said antibody or antigen-binding fragment is a chimeric antibody or antigen-binding fragment thereof.
- 9. A method according to claim 1, wherein said antibody or antigen-binding fragment is a human antibody or antigen-binding fragment thereof.
- 10. A method according to claim 1, wherein said antibody or antigen-binding fragment is a humanized antibody or antigen-binding fragment thereof.
- 11. A method according to claim 10, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more antigen-binding regions of monoclonal antibody 1D9.
- 12. A method according to claim 10, wherein said humanized antibody comprises one or more complementarity-determining regions of monoclonal antibody 1D9.
- 13. A method according to claim 12, wherein said humanized antibody comprises six complementarity-determining regions of monoclonal antibody 1D9.
- 14. A method according to claim 1, wherein said antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab′ fragment and an F(ab′)2 fragment.
- 15. A method according to claim 1, wherein said antibody or antigen-binding fragment thereof is an antibody or fragment having the epitopic specificity of monoclonal antibody 1D9.
- 16. A method according to claim 1, wherein said antibody or antigen-binding fragment thereof is an antibody or fragment which can compete with monoclonal antibody 1D9 for binding to mammalian CC-chemokine receptor 2.
- 17. A method according to claim 1, wherein said antibody or antigen-binding fragment thereof binds a portion of the amino-terminal domain which is from about amino acid 1 to about amino acid 30 of said receptor.
- 18. A method of inhibiting the interaction of a cell bearing mammalian CC-chemokine receptor 2 with a ligand thereof, comprising contacting said cell with an effective amount of monoclonal antibody 1D9 or antigen-binding fragment thereof which binds to mammalian CC-chemokine receptor 2 and inhibits binding of said ligand to the receptor.
RELATED APPLICATION
[0001] This application is a divisional of U.S. patent application Ser. No. 09/121,781, filed Jul. 23, 1998, the entire teachings of which are incorporated herein by reference.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09121781 |
Jul 1998 |
US |
Child |
09905847 |
Jul 2001 |
US |